Earnings calls

Solara Active concall ledger

Every earnings call for SOLARA — management tone, guidance, KPIs and promise tracking, quarter by quarter.

SOLARA · 4 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 15 May 2026Call held 15 May 2026

SOLARA Q4 FY26 Earnings Call Transcript & Analysis

Revenue₹392 crEBITDA₹61 crEBITDA Margin16%Gross Margin₹184 cr

Revenue ₹392 cr; EBITDA ₹61 cr; EBITDA Margin 16%. Revenue of ₹392 crores, up 12% QoQ.

Q3 FY26Published 10 Feb 2026Call held 10 Feb 2026

Revenue₹346 cr+15% YoYEBITDA₹37 crGross Margin47%

Revenue ₹346 cr (+15% YoY); EBITDA ₹37 cr; Gross Margin 47%. Non-ibuprofen growth API business achieved 56% gross margin and 25% EBITDA.

Q2 FY26Published 05 Nov 2025Call held 05 Nov 2025

Revenue₹314 crEBITDA₹35 crEBITDA Margin11%Gross Margin51%

Revenue ₹314 cr; EBITDA ₹35 cr; EBITDA Margin 11%. Revenue declined marginally Q-o-Q to INR314 crores.

Q4 FY25Published 25 Jul 2025Call held 25 Jul 2025

Revenue₹320 crEBITDA₹57 cr+36% YoYPAT105 millionGross Margin54%EPS₹2.5

Revenue ₹320 cr; EBITDA ₹57 cr (+36% YoY); PAT 105 million. Revenue grew 15% QoQ to ₹320 crores.